Evidence map›Paper›PMID 42295667›Full record

ArticleUpdates in surgery2026

Perioperative risk factors for disease recurrence following ileocecal resection in Crohn's disease: implications for early immunosuppressive therapy.

Martijn Depuydt, Filip Baert, Esther Bossuyt, Anna Gheskiere, Peter Lissens, Hans De Loof, Paul Pattyn

Abstract read
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martijn DepuydtGeneral, Abdominal and Thoracic Surgery, AZ Delta, Deltalaan 1, 8800, Roeselare, Belgium. martijn.depuydt@gmail.com.ORCID http://orcid.org/0000-0003-3553-5091
Filip BaertGastroenterology, AZ Delta, Roeselare, Belgium.ORCID http://orcid.org/0009-0003-4370-6708
Esther BossuytFaculty of Medicine, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0009-0009-6190-4453
Anna GheskiereFaculty of Medicine, KU Leuven, Leuven, Belgium.
Peter LissensGeneral, Abdominal and Thoracic Surgery, AZ Delta, Deltalaan 1, 8800, Roeselare, Belgium.
Hans De LoofGeneral, Abdominal and Thoracic Surgery, AZ Delta, Deltalaan 1, 8800, Roeselare, Belgium.
Paul PattynGeneral, Abdominal and Thoracic Surgery, AZ Delta, Deltalaan 1, 8800, Roeselare, Belgium.ORCID http://orcid.org/0000-0002-6772-9360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCrohn's disease is a chronic inflammatory bowel disease (IBD) affecting 1.85-10.5 individuals per 100,000 per year. Approximately 30-50% of patients still require surgery during their lifetime. While patients with Crohn's disease are at increased risk of postoperative complications, ileocecal resection remains a viable alternative to medical treatment for terminal ileitis. However, the optimal timing for initiating immunosuppressive therapy postoperatively, whether as a prophylactic measure or upon disease recurrence, remains a topic of debate. This study aimed to identify perioperative risk factors for disease recurrence to support a more tailored approach to early postoperative immunosuppressive therapy.

methodsA retrospective chart review was conducted on all patients who underwent ileocecal resection for Crohn's disease between January 2006 and March 2023. The primary endpoint was the need for advanced medical therapy for Crohn's disease within one year postoperatively. Secondary endpoints included clinical and endoscopic recurrence after one year and time to start advanced medical therapy, clinical recurrence and endoscopic recurrence. The following possible prognostic factors were analysed: age, sex, smoking status, BMI, presence of perianal disease, length of resection, advanced medical therapy, previous resection, previous appendectomy, behaviour classification, and disease extent.

resultsA total of 129 patients were included, with a median follow-up of 98 months. Higher BMI category was the most robust predictor for advanced medical therapy at one year (OR = 1.88, 95% CI [1.20-2.95], P = .006) and for time to endoscopic recurrence (HR = 1.62, 95% CI [1.21-2.16], P = .001). Previous bowel resection was significantly associated with advanced medical therapy on univariable analysis (OR = 3.25, 95% CI [1.39-7.61], P = .007), with a trend persisting in the multivariable model (OR = 2.49, P = .06). Perianal disease was associated with shorter medication-free survival (HR = 1.64, 95% CI [1.03-2.62], P = .04). Penetrating disease behaviour was linked to earlier start of advanced medical therapy on univariable analysis (HR = 1.60, 95% CI [1.02-2.50], P = .04). Female sex showed a trend toward a protective effect on clinical recurrence (OR = 0.47, P = .08).

conclusionIn this cohort, ileocecal resection was associated with substantial symptomatic improvement. To our knowledge, this study is the first to identify increased BMI as an independent risk factor. Furthermore, it suggests that perianal disease may be associated with increased recurrence risk, while female sex may be associated with lower risk. A more contemporary estimate of surgical reintervention after ileocecal resection for Crohn's disease may be closer to 12% rather than the historically cited 35%, based on long-term follow-up in this cohort.

Indexed as

CecumCrohn DiseaseIleumImmunosuppressive AgentsAdultColorectal Surgical ProceduresFemaleFollow-Up StudiesHumansMaleMiddle AgedPerioperative PeriodPostoperative ComplicationsRecurrenceRetrospective StudiesRisk FactorsImmunosuppressive AgentsCrohn’s diseaseIleocecal resectionImmunosuppressantsRecurrenceRisk factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.